osmin trials. Most studies included patients
with varicose veins (C2), but also with more advanced
CVI, like venous edema (C3), skin changes (C4-C5), venous
ulcers (C6). Pooled data analysis of VADs was given,
although the document also includes breakdown of the
different effect of individual products as well. The number of patients included in many studies was low and the

18

Gloviczki et al

Journal of Vascular Surgery: Venous and Lymphatic Disorders
January 2024

Table VI. Summary of the pharmacologic properties of venoactive drugs (VADs) used for chronic venous disordersa
Pharmacologic properties
VADs

Venous
tone

Vein wall
and valve

Capillary
leakage

MPFF

þ

þ

þ

Ruscus extracts

þ

þ

þ

þ

þ

Hydroxyethylrutosides

þ

þ

þ

Calcium dobesilate

þ

þ

þ

Horse chestnut
extract/escin

þ

þ

þ

þ

þ

Red vine leaf extract

Lymphatic Hemorheological Antioxidant Inﬂammatory Endothelial
drainage
disorders
properties
reaction
function
þ

þ

þ

þ

þ

þ

þ

þ

þ

þ

þ

þ

þ

Sulodexide

þ

MPFF, Micronized puriﬁed ﬂavonoid fraction.
a
Adapted from Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B, et al. Management of chronic venous disorders of the
lower limbs. Guidelines According to Scientiﬁc Evidence. Part I. Int Angiol. 2018; 37(3):181-254.57

follow-up was short. The review found moderatecertainty evidence that phlebotonics in patients with
CVI probably reduced edema in the lower legs,
compared with placebo (risk ratio [RR] 0.70; 95% conﬁdence interval [CI] 0.63-0.7